In-depth investigation of analgesic activity of N-(4-methoxybenzyl)-4-methyl-2.2-dioxo-1H-2 λ6.1-benzothiazine-3-carboxamide derivate on different models of pain perception

  • O. V. Malchenko National Pirogov Memorial Medical University, Vinnytsya, Ukraine
Keywords: N-(4-methoxybenzyl)-4-methyl-2.2-dioxo-1H-2 λ6.1-benzothiazine-3-carboxamide, analgesic effect, acetic-acid-induced writhing test, tail-flick test, adjuvant arthritis, diabetic neuropathy, rats.


Among N-(4-methoxybenzyl)-4-methyl-2.2-dioxo-1H-2 λ6.1-benzothiazine-3-carboxamide derivates, the compound methoxybenzyl-amide derivative 4-methyl-2.2-dioxo-1H-2λ6.1-benzothiazine-3-carboxylic acid (compound NI-9) with pronounced analgesic and anti-inflammatory activities, which was superior to those of diclofenac and lornoxicam in the model of carrageenan edema. The aim of the study was to investigate the analgesic effect of benzothiazine-3-carboxamide derivative on different models of somatic and neuropathic pain syndromes. The study was performed on 91 male Wistar rats. Compound NI-9 and reference drugs meloxicam, diclofenac and gabapentin were administered intragastrically at doses of 3, 5, 8 and 5 mg/kg, respectively, corresponding to their ED50 in analgesic activity. Acetic spasms in mice, a model of thermal irritation of the tail flick in rats, as well as adjuvant arthritis and diabetic polyneuropathy were selected as models of pain syndromes. The results were processed in the program STATISTICA 10.0 using non-parametric methods. The results showed that methoxybenzyl-amide derivative 4-methyl-2.2-dioxo-1H-2λ6.1-benzothiazine-3-carboxylic acid (compound NI-9) has a pronounced analgesic effect on various models of pain syndromes, both somatic and inflammatory. and of neurogenic origin. The analgesic activity of the compound NI-9 in the model of acetic acid cramps in mice and thermal irritation in rats was 38.09 and 49.75 %, respectively, which was higher than that of meloxicam (36.73 and 45.68 %), and inferior to diclofenac (41.95 and 55.95 %). In the model of the systemic inflammatory process (adjuvant arthritis), the analgesic effect of NI-9 was statistically superior to meloxicam and diclofenac (43.32 % vs. 26.26 and 33.69 %). In a model of neuropathic pain syndrome (diabetic neuropathy), the analgesic effect of methoxybenzyl-amide derivative 4-methyl-2.2-dioxo-1H-2λ6.1-benzothiazine-3-carboxylic acid was greater than meloxicam (18.96 vs. 13.34 %), but this figure was lower than that of gaapentin (20.83 %). Further in-depth study of its pharmacodynamics and toxicity will be the theoretical basis for the development on the basis of this biologically active compound of the original drug with analgesic and anti-inflammatory activities.


[1] Atkinson, T. J., & Fudin, J. (2020). Nonsteroidal Antiinflammatory Drugs for Acute and Chronic Pain. Phys Med & Rehabil Clin, 31(2), 219-231. doi: 0.1016/j.pmr.2020.01.002
[2] Banos, J. E., Sanchez, G., Berrendero, F., & Maldonado, R. (2003). Neuropathic pain: some clues for future drug treatments. Mini Rev Med Chem, 3, 719-727. doi: 10.2174/1389557033487773
[3] Burukoglu, D., Baycu, C., Taplamacioglu, F., Sahin, E., & Bektur, E. (2016). Effects of nonsteroidal anti-inflammatory meloxicam on stomach, kidney, and liver of rats. Toxicol Ind Health, 32(6), 980-986. doi: 10.1177/0748233714538484
[4] Calvo, M., Dawes, J. M., & Bennett, D. L. (2012). The role of the immune system in the generation of neuropathic pain. Lancet Neurol, 11(7), 629-642. doi: 10.1016/S1474-4422(12)70134-5
[5] Campbell, J., & Meyer, R. (2006). Mechanisms of neuropathic pain. Neuron, 52(1), 77-92. doi: 10.1016/j.neuron.2006.09.021
[6] Clarke, T. C., Nahin, R. L., Barnes, P. M., & Stussman, B. J. (2016). Use of Complementary Health Approaches for Musculoskeletal Pain Disorders Among Adults: United States, 2012. Natl Health Stat Report, 98, 1-12.
[7] Henschke, N., Kamper S. J., & Maher C. G. (2015). The epidemiology and economic consequences of pain. Mayo Clinic Proceedings, 90(1), 139-147. doi: 10.1016/j.mayocp.2014.09.010
[8] Malchenko, О. V., Voloshchuk, N. І. & Hrymalovska, O. V. (2021). Експериментальне дослідження механізмів аналгезуючої дії похідного 4-метил-2,2-діксо-1H-2λ6,1-бензотіазин-3-карбонової кислоти (сполука NI-9) у щурів [Experimental study of analgesic mechanisms of 4-methyl-2,2-dioxo-1H-2λ6,1-benzothiazine-3-carboxylic acid derivative (compound NI-9) in rat]. Вісник Вінницького національного медичного університету – Reports of Vinnytsia National Medical University, 1(25), 12-17. doi: 10.31393/reports-vnmedical-2021-25(1)-02
[9] Malchenko, О. V., Voloshchuk, N. І. & Pentiuk, N. O. (2020). Investigation of 4-methyl-2.2-dioxo-1H-2λ6,1-benzothiazine-3-carboxamide derivative influence on the biochemical markers of gastric mucosa in rats. Biomedical and Biosocial Anthropology, 41, 36-40. doi: 10.31393/bba41-2020-06
[10] Mironov, А. N. (red). (2012). Руководство по проведению доклинических исследований лекарственных средств. Часть первая [Guidelines for conducting preclinical studies of drugs. Part one]. М.: Гриф и К – М.: Grif and К.
[11] Morgan, B., & Wooden, S. (2018). Diagnosis and treatment of common pain syndromes and disorders. Nurs. Clin. North. Am, 53(3), 349-360. doi: 10.1016/j.cnur.2018.04.004
[12] Nicholas, M., Vlaeyen, J., Rief, W., Barke, A., Aziz, Q., Benoliel, R. ... & Treede, R. D. (2019). The IASP classification of chronic pain for ICD-11: chronic primary pain. PAIN, 160(1), 28-37. doi: 10.1097/j.pain.0000000000001390
[13] Palmer, G. M. (2016). Pain management in the acute care setting: Update and debates. J Paediatr Child Health, 52(2), 213-220. doi: 10.1111/jpc.13134
[14] Stefanov, O. V. (red). (2001). Доклінічні дослідження лікарських засобів: Метод. рекомендації [Preclinical studies of drugs: Method. Recommendations]. K.: VD «Avitsena».
[15] Takeda, K., Sawamura, S., Tamai, H., Sekiyama, H., & Hanaoka, K. (2005). Role for Cyclooxygenase 2 in the Development and Maintenance of Neuropathic Pain and Spinal Glial Activation. Anesthesiology, 103, 837-844.
[16] Treede, R. D., Rief, W., Barke, A., Aziz, Q., Bennett, M. I., Benoliel, R. … & Wang, S. J. (2019). Chronic pain as a symptom or a disease: the IASP Classification of Chronic Pain for the International Classification of Diseases (ICD-11). PAIN, 160(1), 19-27. doi: 10.1097/j.pain.0000000000001384
[17] Ukrainets, I. V., Hamza, G. M., Burian, A. A., Voloshchuk, N. I., Malchenko, O. V., Shishkina, S. V. … & Sim, G. (2018). Molecular Conformations and Biological Activity of N-Hetaryl(aryl)alkyl-4-methyl-2,2-dioxo-1H-2λ6,1-benzothiazine-3-carboxamides. Sci Pharm, 86(4), 50. doi: 10.3390/scipharm86040050
[18] Ukrainets, I. V., Mospanova, E. V., Savchenkova, L. V., & Yankovich, S. I. (2011). 4-Hydroxy-2-quinolones. 195. Synthesis of novel, potential analgesics based on 4-(hetarylmethyl)amino-2-oxo-1,2-dihydroquinoline-3-carboxylic acids. Chem Heterocycl Compd, 47(1), 67-73. doi: 10.1007/s10593-011-0721-4
[19] Ukrainets, I. V., Petrushova, L. A., Fedosov, A. I., Voloshchuk, N. I., Bondarenko, P. S., Shishkina, S. V., … & Sim, G. (2020). Crystal Habits and Biological Properties of N-(4-Trifluoromethylphenyl)-4-Hydroxy-2, 2-Dioxo-1H-2λ6, 1-Benzothiazine-3-Carboxamide. Scientia Pharmaceutica, 88(1), 45-60. doi: 10.3390/scipharm88010001
[20] Wager, J., Brown, D., Kupitz, A., Rosenthal, N., & Zernikow, B. (2020). Prevalence and associated psychosocial and health factors of chronic pain in adolescents: differences by sex and age. European Journal of Pain, 24(4), 761-772. doi: 10.1002/ejp.1526
[21] Yongwoo, J., Minseok, K., & Sun Wook, H. (2020). Molecular mechanisms underlying the actions of arachidonic acid-derived prostaglandins on peripheral nociception. J Neuroinflammation, 17, 30. doi: 10.1186/s12974-020-1703-1
[22] Zhu, X., & Eisenach, J. C. (2003). Cyclooxygenase-1 in the spinal cord is altered after peripheral nerve injury. Anesthesiology, 99, 1175-1179. doi: 10.1097/00000542-200311000-00026
How to Cite
Malchenko , O. V. (2021). In-depth investigation of analgesic activity of N-(4-methoxybenzyl)-4-methyl-2.2-dioxo-1H-2 λ6.1-benzothiazine-3-carboxamide derivate on different models of pain perception. Biomedical and Biosocial Anthropology, (42), 57-62.